These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 3928229)

  • 1. Risk- and cost-benefit analyses of breast screening programs derived from absorbed dose measurements in The Netherlands.
    Zuur C; Broerse JJ
    Diagn Imaging Clin Med; 1985; 54(3-4):211-22. PubMed ID: 3928229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiation risk and mammographic screening of women from 40 to 49 years of age: effect on breast cancer rates and years of life.
    Mattsson A; Leitz W; Rutqvist LE
    Br J Cancer; 2000 Jan; 82(1):220-6. PubMed ID: 10638993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Breast cancer screening policies in developing countries: a cost-effectiveness analysis for India.
    Okonkwo QL; Draisma G; der Kinderen A; Brown ML; de Koning HJ
    J Natl Cancer Inst; 2008 Sep; 100(18):1290-300. PubMed ID: 18780864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
    Hristova L; Hakama M
    Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Radiogenic breast cancer effects of mammographic screening.
    Gohagan JK; Darby WP; Spitznagel EL; Monsees BS; Tome AE
    J Natl Cancer Inst; 1986 Jul; 77(1):71-6. PubMed ID: 3459927
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast cancer screening, outside the population-screening program, of women from breast cancer families without proven BRCA1/BRCA2 mutations: a simulation study.
    Jacobi CE; Nagelkerke NJ; van Houwelingen JH; de Bock GH
    Cancer Epidemiol Biomarkers Prev; 2006 Mar; 15(3):429-36. PubMed ID: 16537697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic considerations in breast cancer screening of older women.
    Brown ML
    J Gerontol; 1992 Nov; 47 Spec No():51-8. PubMed ID: 1430883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recruiting older women for screening mammography.
    Halabi S; Vogel VG; Bondy ML; Vernon SW
    Cancer Detect Prev; 1993; 17(3):359-65. PubMed ID: 8402722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits versus risks from mammography: a critical reassessment.
    Mettler FA; Upton AC; Kelsey CA; Ashby RN; Rosenberg RD; Linver MN
    Cancer; 1996 Mar; 77(5):903-9. PubMed ID: 8608482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estimating personal costs incurred by a woman participating in mammography screening in the National Breast and Cervical Cancer Early Detection Program.
    Ekwueme DU; Hall IJ; Richardson LC; Gardner JG; Royalty J; Thompson TD
    Cancer; 2008 Aug; 113(3):592-601. PubMed ID: 18536027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast cancer screening for women aged 40 to 49 years--what does the evidence mean for New Zealand?
    Baker S; Wall M; Bloomfield A
    N Z Med J; 2005 Aug; 118(1221):U1628. PubMed ID: 16138166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk benefit in mass screening programs for breast cancer.
    Miller AB
    Semin Oncol; 1978 Dec; 5(4):351-9. PubMed ID: 104389
    [No Abstract]   [Full Text] [Related]  

  • 13. [Mammographic screening does not reduce breast cancer mortality].
    Sjönell G; Ståhle L
    Lakartidningen; 1999 Feb; 96(8):904-5, 908-13. PubMed ID: 10089737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness of mammography, MRI, and ultrasonography for breast cancer screening.
    Feig S
    Radiol Clin North Am; 2010 Sep; 48(5):879-91. PubMed ID: 20868891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cost-effectiveness of mammography screening in Norway].
    Kåresen R; Bø JK; Haustveit S; Hervik A; Thoresen SO
    Tidsskr Nor Laegeforen; 1999 Oct; 119(24):3553-9. PubMed ID: 10563171
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening for breast cancer in England: past and future.
    Advisory Committee on Breast Cancer Screening
    J Med Screen; 2006; 13(2):59-61. PubMed ID: 16792825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A model-based comparison of breast cancer screening strategies: mammograms and clinical breast examinations.
    Shen Y; Parmigiani G
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):529-32. PubMed ID: 15734983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Why isn't every woman over 40 in a breast cancer detection program?
    Robertson CL
    West J Med; 1988 Jul; 149(1):111-2. PubMed ID: 3407158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammographic screening for breast cancer: An invited review of the benefits and costs.
    Greif JM
    Breast; 2010 Aug; 19(4):268-72. PubMed ID: 20371181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.